- Home
- / Urogen Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Urogen Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$12.3
2024-10-29
Market Capitalization
$515.9 M
2024-10-29
Revenue
$109.8 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 06, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.2M | 1.1M | 18.0K | 11.8M | 48.0M | 64.4M | 82.7M | 90.4M | 109.8M |
| Cost of goods sold | 600.0K | 1.8M | 1.0M | 5.2M | 7.7M | 9.4M | 8.9M | 12.4M | |
| Gross profit | 7.6M | (675.0K) | 10.8M | 42.9M | 56.7M | 73.4M | 81.5M | 97.3M | |
| Gross profit margin, % | 92.6% | -59.8% | 91.4% | 88.1% | 90.2% | 88.7% | |||
| General and administrative expense | 8.8M | 39.6M | 60.2M | 90.2M | 87.5M | 82.8M | 93.3M | 121.2M | 155.1M |
| Operating expense total | 27.5M | 76.5M | 109.5M | 137.5M | 135.2M | 135.7M | 138.9M | 178.3M | 222.2M |
| EBIT | (19.9M) | (77.2M) | (109.5M) | (126.7M) | (92.3M) | (79.0M) | (65.5M) | (96.8M) | (124.9M) |
| EBIT margin, % | -244.5% | -6842.2% | -608211.1% | -1074.2% | -122.8% | -107.1% | -113.7% | ||
| Interest income | 1.0M | 2.6M | 8.9M | 5.3M | |||||
| Pre tax profit | (20.0M) | (75.5M) | (105.1M) | (125.1M) | (109.4M) | (108.0M) | (98.3M) | (124.0M) | (153.4M) |
| Income tax expense | 19.0K | 125.0K | 3.4M | 1.4M | 1.8M | 3.9M | 2.8M | 78.0K | |
| Net Income | (20.0M) | (75.7M) | (105.1M) | (128.5M) | (110.8M) | (109.8M) | (102.2M) | (126.9M) | (153.5M) |